Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 11/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4138801 | 1.00 | HSD11B1 (0.57) | HSD11B1TSHRMAPTSMN1; SMN2NPC1 | |
| SCHEMBL192704 | 0.89 | ALDH1A1 (0.56) | HSD11B1TSHRMAPTSMN1; SMN2NPC1 | |
| SCHEMBL192705 | 0.89 | ALDH1A1 (0.56) | HSD11B1TSHRMAPTSMN1; SMN2NPC1 | |
| SCHEMBL8146112 | 0.89 | HCRTR1 (0.50) | TSHRMAPTSMN1; SMN2ALDH1A1HCRTR1 | |
| SCHEMBL29891783 | 0.89 | HCRTR1 (0.50) | TSHRMAPTSMN1; SMN2ALDH1A1HCRTR1 | |
| SCHEMBL5767758 | 0.89 | TSHR (0.57) | HSD11B1TSHRMAPTNPC1ALDH1A1 | |
| SCHEMBL192463 | 0.89 | TSHR (0.57) | HSD11B1TSHRMAPTNPC1ALDH1A1 | |
| SCHEMBL192159 | 0.89 | HSD11B1 (0.54) | HSD11B1TSHRMAPTSMN1; SMN2NPC1 | |
| SCHEMBL192160 | 0.89 | HSD11B1 (0.54) | HSD11B1TSHRMAPTSMN1; SMN2NPC1 | |
| SCHEMBL193157 | 0.87 | HSD11B1 (0.70) | HSD11B1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090197897-A1 | Novel Oxadiazole Derivatives and Their Use as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | ADDEX PHARMA SA (CH) | 2009-08-06 | — | — | US | disclosed |
| EP-1896463-A2 | NOVEL OXADIAZOLE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX Pharma S.A. (CH) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006123249-A2 | NOVEL OXADIAZOLE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197897-A1 | Novel Oxadiazole Derivatives and Their Use as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | GRM5, GRM2, GRM3 | HSD11B1 3098/4885TSHR 560/4885MAPT 2177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.